Perfil
Jon Filderman is currently working as the Secretary & Director at Acceleron Pharma, Inc. since 2021.
Prior to this, he worked as a Director at Organon & Co. and as a Manager at Rosetta Inpharmatics LLC.
Cargos activos de Jon Filderman
| Empresas | Cargo | Inicio |
|---|---|---|
| ACCELERON PHARMA INC. | Director/Board Member | 19/11/2021 |
Antiguos cargos conocidos de Jon Filderman.
| Empresas | Cargo | Fin |
|---|---|---|
| ORGANON & CO. | Director/Board Member | 02/06/2021 |
Rosetta Inpharmatics LLC
 Rosetta Inpharmatics LLC BiotechnologyHealth Technology Rosetta Inpharmatics LLC designed and implemented DNA microarray gene expression systems. The company provided software for use in informational genomics. The company was founded in may 29, 2009 and was headquartered in Seattle, WA. | Corporate Officer/Principal | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| ORGANON & CO. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Rosetta Inpharmatics LLC
Rosetta Inpharmatics LLC BiotechnologyHealth Technology Rosetta Inpharmatics LLC designed and implemented DNA microarray gene expression systems. The company provided software for use in informational genomics. The company was founded in may 29, 2009 and was headquartered in Seattle, WA. | Health Technology |
Acceleron Pharma, Inc.
 Acceleron Pharma, Inc. BiotechnologyHealth Technology Acceleron Pharma, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to patients with chronic anemia associated within a wide range of blood diseases; ACE-083, designed for the treatment of focal muscle disorders; and Sotatercept, designed to treat pulmonary arterial hypertension. The company was founded by John L. Knopf and Thomas P. Maniatis in June 2003 and is headquartered in Cambridge, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Jon Filderman
